DE69209173D1 - Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten - Google Patents

Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten

Info

Publication number
DE69209173D1
DE69209173D1 DE69209173T DE69209173T DE69209173D1 DE 69209173 D1 DE69209173 D1 DE 69209173D1 DE 69209173 T DE69209173 T DE 69209173T DE 69209173 T DE69209173 T DE 69209173T DE 69209173 D1 DE69209173 D1 DE 69209173D1
Authority
DE
Germany
Prior art keywords
biologically active
polypeptides
peptides
active proteins
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69209173T
Other languages
English (en)
Other versions
DE69209173T2 (de
Inventor
William David Steber
Susan Mancini Cady
David Farley Johnson
Theresa Rice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of DE69209173D1 publication Critical patent/DE69209173D1/de
Application granted granted Critical
Publication of DE69209173T2 publication Critical patent/DE69209173T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/07—Stiffening bandages
    • A61L15/10—Stiffening bandages containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
DE69209173T 1991-06-24 1992-04-29 Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten Expired - Fee Related DE69209173T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71989891A 1991-06-24 1991-06-24

Publications (2)

Publication Number Publication Date
DE69209173D1 true DE69209173D1 (de) 1996-04-25
DE69209173T2 DE69209173T2 (de) 1996-11-28

Family

ID=24891827

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69209173T Expired - Fee Related DE69209173T2 (de) 1991-06-24 1992-04-29 Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten

Country Status (24)

Country Link
EP (1) EP0523330B1 (de)
JP (1) JP3597205B2 (de)
KR (1) KR100221031B1 (de)
CN (1) CN1050301C (de)
AT (1) ATE135565T1 (de)
AU (1) AU656200B2 (de)
BR (1) BR9202374A (de)
CA (1) CA2071757C (de)
DE (1) DE69209173T2 (de)
DK (1) DK0523330T3 (de)
ES (1) ES2087337T3 (de)
GE (1) GEP19970992B (de)
GR (1) GR3019457T3 (de)
HU (1) HU217547B (de)
IE (1) IE74398B1 (de)
IL (1) IL102287A (de)
LV (1) LV11816B (de)
MD (1) MD1394G2 (de)
MX (1) MX9203175A (de)
RU (1) RU2080119C1 (de)
SG (1) SG47955A1 (de)
TW (1) TW215058B (de)
UA (1) UA26137C2 (de)
ZA (1) ZA924613B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
JP2001058955A (ja) * 1999-06-17 2001-03-06 Inst Of Physical & Chemical Res 生理活性ペプチド徐放性製剤
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
MXPA03000073A (es) 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
JP2005145821A (ja) * 2003-11-11 2005-06-09 Kao Corp 打錠製剤
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271113A (en) * 1978-04-17 1981-06-02 Alza Corporation Process for forming a passageway in an osmotic device
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4863736A (en) * 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
WO1992002211A1 (en) * 1990-08-09 1992-02-20 Endocon, Inc. Multiple drug delivery system

Also Published As

Publication number Publication date
AU656200B2 (en) 1995-01-27
SG47955A1 (en) 1998-04-17
JP3597205B2 (ja) 2004-12-02
CN1050301C (zh) 2000-03-15
MD1394G2 (ro) 2000-11-30
IL102287A0 (en) 1993-01-14
ZA924613B (en) 1993-03-31
EP0523330A1 (de) 1993-01-20
UA26137C2 (uk) 1999-06-07
ES2087337T3 (es) 1996-07-16
CA2071757A1 (en) 1992-12-25
ATE135565T1 (de) 1996-04-15
KR930000131A (ko) 1993-01-15
HU217547B (hu) 2000-02-28
EP0523330B1 (de) 1996-03-20
GEP19970992B (en) 1997-11-20
LV11816B (en) 1997-12-20
IE74398B1 (en) 1997-07-30
JPH05186363A (ja) 1993-07-27
GR3019457T3 (en) 1996-06-30
AU1847092A (en) 1993-01-07
RU2080119C1 (ru) 1997-05-27
IE922020A1 (en) 1992-12-30
MD1394F2 (en) 2000-01-31
MD940370A (en) 1996-06-28
CA2071757C (en) 2003-06-10
MX9203175A (es) 1993-04-01
CN1068965A (zh) 1993-02-17
LV11816A (lv) 1997-08-20
DE69209173T2 (de) 1996-11-28
DK0523330T3 (da) 1996-04-15
HU9202092D0 (en) 1992-09-28
TW215058B (de) 1993-10-21
HUT61486A (en) 1993-01-28
BR9202374A (pt) 1993-01-26
IL102287A (en) 2000-06-01
KR100221031B1 (ko) 1999-09-15

Similar Documents

Publication Publication Date Title
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
NZ216832A (en) Bovine growth hormone implant
EP0526544A4 (en) Therapeutic uses of actin-binding compounds
DE69209173D1 (de) Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
FI954978A (fi) Modifioidut proteiini- ja peptidilääkeaineet
ES2031806T3 (es) Factor de permeabilidad vascular humano.
EP0212474A3 (de) Morphogenetische Knochenpeptide
KR910007542A (ko) 폴리펩타이드의 서방형 조성물
IL102346A0 (en) Cysteine depleted il-6 muteins
FI885851A (fi) Biologiskt resorberbart implantationsmaterial samt foerfarande foer framstaellning daerav.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
CO4230067A1 (es) Composicion cosmetica para el cuidado de la piel
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
BG60657B2 (en) Human recombinant interleukin-2 muteins
IL97372A0 (en) Method for the quantitative determination of the biologically active form of the human nerve growth factor in protein liquids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

8339 Ceased/non-payment of the annual fee